Long-term first line medical treatment in a 4-year-old girl with Xq26.3 microduplication-negative somatotropinoma. Case report and literature review

Chiara Maggioli, Paola Cambiaso, Sara Ciccone, Giovanna Stefania Colafati, Marco Cappa

Research output: Contribution to journalArticle

Abstract

Growth hormone (GH) secreting adenoma represents a therapeutic challenge in childhood. Because of its rarity no treatment guidelines are available and pediatric management often results from recommendations issued for adults. We report a case of a 4-year-old girl with somatotropinoma successfully treated with only medical treatment. She presented with tall stature and history of growth acceleration. Imaging and laboratory confirmed the diagnosis of GH secreting macroadenoma. She started medical treatment with a somatostatin analogue and a dopamine agonist. During an 8-year follow-up period, a good clinical control of the disease and a shrinkage of the adenoma have been demonstrated. At the last observation she achieved normal near-adult height and pubertal development. According to our experience and limited literature evidences, first line treatment with somatostatin analogues can be attempted in patients with somatotropinoma. This approach seems to be able to control the clinical course of the disease, allowing to postpone transphenoidal surgery to adult age or to avoid it.

Original languageEnglish
Pages (from-to)497-501
Number of pages5
JournalJournal of Pediatric Endocrinology and Metabolism
Volume29
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Somatostatin
Adenoma
Growth Hormone
Therapeutics
Clinical Laboratory Techniques
Dopamine Agonists
Observation
Guidelines
Pediatrics
Growth

Keywords

  • children
  • GH-secreting adenoma
  • pituitary
  • somatostatin analogues

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Long-term first line medical treatment in a 4-year-old girl with Xq26.3 microduplication-negative somatotropinoma. Case report and literature review. / Maggioli, Chiara; Cambiaso, Paola; Ciccone, Sara; Colafati, Giovanna Stefania; Cappa, Marco.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 29, No. 4, 01.04.2016, p. 497-501.

Research output: Contribution to journalArticle

@article{a0d4a16134194039ad39e8a543255742,
title = "Long-term first line medical treatment in a 4-year-old girl with Xq26.3 microduplication-negative somatotropinoma. Case report and literature review",
abstract = "Growth hormone (GH) secreting adenoma represents a therapeutic challenge in childhood. Because of its rarity no treatment guidelines are available and pediatric management often results from recommendations issued for adults. We report a case of a 4-year-old girl with somatotropinoma successfully treated with only medical treatment. She presented with tall stature and history of growth acceleration. Imaging and laboratory confirmed the diagnosis of GH secreting macroadenoma. She started medical treatment with a somatostatin analogue and a dopamine agonist. During an 8-year follow-up period, a good clinical control of the disease and a shrinkage of the adenoma have been demonstrated. At the last observation she achieved normal near-adult height and pubertal development. According to our experience and limited literature evidences, first line treatment with somatostatin analogues can be attempted in patients with somatotropinoma. This approach seems to be able to control the clinical course of the disease, allowing to postpone transphenoidal surgery to adult age or to avoid it.",
keywords = "children, GH-secreting adenoma, pituitary, somatostatin analogues",
author = "Chiara Maggioli and Paola Cambiaso and Sara Ciccone and Colafati, {Giovanna Stefania} and Marco Cappa",
year = "2016",
month = "4",
day = "1",
doi = "10.1515/jpem-2015-0036",
language = "English",
volume = "29",
pages = "497--501",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "4",

}

TY - JOUR

T1 - Long-term first line medical treatment in a 4-year-old girl with Xq26.3 microduplication-negative somatotropinoma. Case report and literature review

AU - Maggioli, Chiara

AU - Cambiaso, Paola

AU - Ciccone, Sara

AU - Colafati, Giovanna Stefania

AU - Cappa, Marco

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Growth hormone (GH) secreting adenoma represents a therapeutic challenge in childhood. Because of its rarity no treatment guidelines are available and pediatric management often results from recommendations issued for adults. We report a case of a 4-year-old girl with somatotropinoma successfully treated with only medical treatment. She presented with tall stature and history of growth acceleration. Imaging and laboratory confirmed the diagnosis of GH secreting macroadenoma. She started medical treatment with a somatostatin analogue and a dopamine agonist. During an 8-year follow-up period, a good clinical control of the disease and a shrinkage of the adenoma have been demonstrated. At the last observation she achieved normal near-adult height and pubertal development. According to our experience and limited literature evidences, first line treatment with somatostatin analogues can be attempted in patients with somatotropinoma. This approach seems to be able to control the clinical course of the disease, allowing to postpone transphenoidal surgery to adult age or to avoid it.

AB - Growth hormone (GH) secreting adenoma represents a therapeutic challenge in childhood. Because of its rarity no treatment guidelines are available and pediatric management often results from recommendations issued for adults. We report a case of a 4-year-old girl with somatotropinoma successfully treated with only medical treatment. She presented with tall stature and history of growth acceleration. Imaging and laboratory confirmed the diagnosis of GH secreting macroadenoma. She started medical treatment with a somatostatin analogue and a dopamine agonist. During an 8-year follow-up period, a good clinical control of the disease and a shrinkage of the adenoma have been demonstrated. At the last observation she achieved normal near-adult height and pubertal development. According to our experience and limited literature evidences, first line treatment with somatostatin analogues can be attempted in patients with somatotropinoma. This approach seems to be able to control the clinical course of the disease, allowing to postpone transphenoidal surgery to adult age or to avoid it.

KW - children

KW - GH-secreting adenoma

KW - pituitary

KW - somatostatin analogues

UR - http://www.scopus.com/inward/record.url?scp=84969132757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969132757&partnerID=8YFLogxK

U2 - 10.1515/jpem-2015-0036

DO - 10.1515/jpem-2015-0036

M3 - Article

VL - 29

SP - 497

EP - 501

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 4

ER -